Pietro Veglianese

List of Publications by Year
in descending order

59 papers	2,846 citations	186265 28 h-index	189892 50 g-index
59 all docs	59 docs citations	59 times ranked	4323 citing authors

#	Article	IF	Citations
1	Biomaterial-Mediated Factor Delivery for Spinal Cord Injury Treatment. Biomedicines, 2022, 10, 1673.	3.2	9
2	Functionalized nanogel for treating activated astrocytes in spinal cord injury. Journal of Controlled Release, 2021, 330, 218-228.	9.9	25
3	Biphasic Porous Structures formed by Monomer/Water Interface Stabilization with Colloidal Nanoparticles. Advanced Materials Interfaces, 2021, 8, 2100991.	3.7	4
4	Biphasic Porous Structures formed by Monomer/Water Interface Stabilization with Colloidal Nanoparticles (Adv. Mater. Interfaces 21/2021). Advanced Materials Interfaces, 2021, 8, 2170119.	3.7	0
5	Introduction to spinal cord injury as clinical pathology. , 2020, , 1-12.		3
6	Paracrine effects for spinal cord injury regeneration. , 2020, , 203-221.		1
7	Effects of primary amine-based coatings on microglia internalization of nanogels. Colloids and Surfaces B: Biointerfaces, 2020, 185, 110574.	5.0	7
8	Selective Modulation of A1 Astrocytes by Drug-Loaded Nano-Structured Gel in Spinal Cord Injury. ACS Nano, 2020, 14, 360-371.	14.6	94
9	Regenerative medicine for spinal cord injury: focus on stem cells and biomaterials. Expert Opinion on Biological Therapy, 2020, 20, 1203-1213.	3.1	20
10	A refinement approach in a mouse model of rehabilitation research. Analgesia strategy, reduction approach and infrared thermography in spinal cord injury. PLoS ONE, 2019, 14, e0224337.	2.5	15
11	Stem cell paracrine effect and delivery strategies for spinal cord injury regeneration. Journal of Controlled Release, 2019, 300, 141-153.	9.9	56
12	Nanovector-Mediated Drug Delivery in Spinal Cord Injury: A Multitarget Approach. ACS Chemical Neuroscience, 2019, 10, 1173-1182.	3.5	20
13	How can nanovectors be used to treat spinal cord injury?. Nanomedicine, 2019, 14, 3123-3125.	3.3	3
14	Title is missing!. , 2019, 14, e0224337.		0
15	Title is missing!. , 2019, 14, e0224337.		0
16	Title is missing!. , 2019, 14, e0224337.		0
17	Title is missing!. , 2019, 14, e0224337.		0
18	Mesenchymal stem cells encapsulated into biomimetic hydrogel scaffold gradually release CCL2 chemokine in situ preserving cytoarchitecture and promoting functional recovery in spinal cord injury. Journal of Controlled Release, 2018, 278, 49-56.	9.9	80

#	Article	IF	Citations
19	Microwave-assisted synthesis of TEMPO-labeled hydrogels traceable with MRI. Soft Matter, 2018, 14, 558-565.	2.7	15
20	Profiling of orthosteric and allosteric group-III metabotropic glutamate receptor ligands on various G protein-coupled receptors with Tag-liteÂ® assays. Neuropharmacology, 2018, 140, 233-245.	4.1	6
21	Novel functionalization strategies to improve drug delivery from polymers. Expert Opinion on Drug Delivery, 2017, 14, 1305-1313.	5.0	23
22	Double conjugated nanogels for selective intracellular drug delivery. RSC Advances, 2017, 7, 30345-30356.	3.6	15
23	Current Options for Cell Therapy in Spinal Cord Injury. Trends in Molecular Medicine, 2017, 23, 831-849.	6.7	141
24	Chemoselective functionalization of nanogels for microglia treatment. European Polymer Journal, 2017, 94, 143-151.	5.4	17
25	Improving the pharmacodynamic and pharmacological profile of bioactive molecules using biopolymers. , 2017, , 285-302.		1
26	Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNF<i>Î±</i>. Mediators of Inflammation, 2017, 2017, 1-16.	3.0	45
27	3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. Scientific Reports, 2016, 6, 37027.	3.3	58
28	Non-invasive in vitro and in vivo monitoring of degradation of fluorescently labeled hyaluronan hydrogels for tissue engineering applications. Acta Biomaterialia, 2016, 30, 188-198.	8.3	80
29	Modulators of microglia: a patent review. Expert Opinion on Therapeutic Patents, 2016, 26, 427-437.	5.0	23
30	A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury. Biomaterials, 2016, 75, 135-147.	11.4	141
31	Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury. Biomaterials, 2016, 75, 13-24.	11.4	110
32	Multidrug encapsulation within self-assembled 3D structures formed by biodegradable nanoparticles. European Polymer Journal, 2015, 68, 216-225.	5.4	5
33	Nanovectorâ€mediated drug delivery for spinal cord injury treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2014, 6, 506-515.	6.1	24
34	Bone Marrow Mesenchymal Stromal Cells Drive Protective M2 Microglia Polarization After Brain Trauma. Neurotherapeutics, 2014, 11, 679-695.	4.4	140
35	Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. Journal of Controlled Release, 2014, 174, 15-26.	9.9	100
36	Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest. Heart Rhythm, 2014, 11, 1641-1647.	0.7	9

#	Article	IF	Citations
37	Selective Nanovector Mediated Treatment of Activated Proinflammatory Microglia/Macrophages in Spinal Cord Injury. ACS Nano, 2013, 7, 9881-9895.	14.6	136
38	Tunable hydrogelâ€"Nanoparticles release system for sustained combination therapies in the spinal cord. Colloids and Surfaces B: Biointerfaces, 2013, 108, 169-177.	5.0	38
39	Current options for drug delivery to the spinal cord. Expert Opinion on Drug Delivery, 2013, 10, 385-396.	5.0	61
40	Soluble AÎ² oligomer-induced synaptopathy: c-Jun N-terminal kinase's role. Journal of Molecular Cell Biology, 2013, 5, 277-279.	3.3	28
41	Sustained Delivery of Chondroitinase ABC from Hydrogel System. Journal of Functional Biomaterials, 2012, 3, 199-208.	4.4	16
42	Neuroprotective Effects of Toll-Like Receptor 4 Antagonism in Spinal Cord Cultures and in a Mouse Model of Motor Neuron Degeneration. Molecular Medicine, 2012, 18, 971-981.	4.4	66
43	Chemical engineering approach to regenerative medicine. Chemical Papers, 2012, 66, .	2.2	0
44	Specific inhibition of the JNK pathway promotes locomotor recovery and neuroprotection after mouse spinal cord injury. Neurobiology of Disease, 2012, 46, 710-721.	4.4	39
45	Multiple drug delivery hydrogel system for spinal cord injury repair strategies. Journal of Controlled Release, 2012, 159, 271-280.	9.9	84
46	The Toxicity of a Mutant Prion Protein Is Cell-Autonomous, and Can Be Suppressed by Wild-Type Prion Protein on Adjacent Cells. PLoS ONE, 2012, 7, e33472.	2.5	13
47	Hydrogels in Spinal Cord Injury Repair Strategies. ACS Chemical Neuroscience, 2011, 2, 336-345.	3.5	142
48	Intracerebroventricular Administration of Human Umbilical Cord Blood Cells Delays Disease Progression in Two Murine Models of Motor Neuron Degeneration. Rejuvenation Research, 2011, 14, 623-639.	1.8	44
49	In situ agarâ€"carbomer hydrogel polycondensation: A chemical approach to regenerative medicine. Materials Letters, 2011, 65, 1688-1692.	2.6	21
50	c-Jun N-terminal Kinase Regulates Soluble AÎ² Oligomers and Cognitive Impairment in AD Mouse Model. Journal of Biological Chemistry, 2011, 286, 43871-43880.	3.4	74
51	Characterization and Degradation Behavior of Agarâ€"Carbomer Based Hydrogels for Drug Delivery Applications: Solute Effect. International Journal of Molecular Sciences, 2011, 12, 3394-3408.	4.1	32
52	Mutant Prion Protein Expression Is Associated with an Alteration of the Rab GDP Dissociation Inhibitor Î± (GDI)/Rab11 Pathway. Molecular and Cellular Proteomics, 2010, 9, 611-622.	3.8	35
53	A New Fluorogenic Peptide Determines Proteasome Activity in Single Cells. Journal of Medicinal Chemistry, 2010, 53, 7452-7460.	6.4	20
54	Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosisâ€. Human Molecular Genetics, 2009, 18, 82-96.	2.9	146

#	Article	IF	Citations
55	Distribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALS. Neuroscience Letters, 2007, 412, 73-77.	2.1	50
56	Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Molecular and Cellular Neurosciences, 2006, 31, 218-231.	2.2	92
57	Inter- and Intracellular Signaling in Amyotrophic Lateral Sclerosis: Role of p38 Mitogen-Activated Protein Kinase. Neurodegenerative Diseases, 2005, 2, 128-134.	1.4	42
58	Anticonvulsant and Antiepileptogenic Effects Mediated by Adeno-Associated Virus Vector Neuropeptide Y Expression in the Rat Hippocampus. Journal of Neuroscience, 2004, 24, 3051-3059.	3.6	222
59	Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Molecular and Cellular Neurosciences, 2003, 23, 180-192.	2.2	155